company background image
BCDA

BioCardia NasdaqCM:BCDA Stock Report

Last Price

US$2.30

Market Cap

US$46.1m

7D

-3.4%

1Y

-5.3%

Updated

09 Feb, 2023

Data

Company Financials +

BCDA Stock Overview

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases.

BCDA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

BioCardia, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BioCardia
Historical stock prices
Current Share PriceUS$2.30
52 Week HighUS$2.85
52 Week LowUS$1.10
Beta1.09
1 Month Change-2.37%
3 Month Change24.32%
1 Year Change-5.35%
3 Year Change-47.13%
5 Year Change-88.44%
Change since IPO-83.10%

Recent News & Updates

Recent updates

BioCardia stock rises on contract for delivery products for BlueRock's cell therapies

Aug 24

Will BioCardia (NASDAQ:BCDA) Spend Its Cash Wisely?

Aug 24
Will BioCardia (NASDAQ:BCDA) Spend Its Cash Wisely?

Here's Why We're Watching BioCardia's (NASDAQ:BCDA) Cash Burn Situation

May 10
Here's Why We're Watching BioCardia's (NASDAQ:BCDA) Cash Burn Situation

We Think BioCardia (NASDAQ:BCDA) Needs To Drive Business Growth Carefully

Jan 06
We Think BioCardia (NASDAQ:BCDA) Needs To Drive Business Growth Carefully

We Think BioCardia (NASDAQ:BCDA) Needs To Drive Business Growth Carefully

Sep 23
We Think BioCardia (NASDAQ:BCDA) Needs To Drive Business Growth Carefully

Why I've Taken A Small Position In BioCardia

Jun 14

Shareholders May Not Be So Generous With BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation And Here's Why

Jun 08
Shareholders May Not Be So Generous With BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation And Here's Why

Is BioCardia (NASDAQ:BCDA) In A Good Position To Deliver On Growth Plans?

May 20
Is BioCardia (NASDAQ:BCDA) In A Good Position To Deliver On Growth Plans?

BioCardia issued U.S. patent for Helix Biotherapeutic Delivery system

Dec 30

BioCardia slips 11% on launch of direct offering

Dec 16

BioCardia says DSMB feedback on cell therapy data in heart failure study anticipated soon

Dec 14

What We Learned About BioCardia's (NASDAQ:BCDA) CEO Compensation

Dec 14
What We Learned About BioCardia's (NASDAQ:BCDA) CEO Compensation

Shareholder Returns

BCDAUS BiotechsUS Market
7D-3.4%-1.8%-1.8%
1Y-5.3%1.9%-10.9%

Return vs Industry: BCDA underperformed the US Biotechs industry which returned 2.9% over the past year.

Return vs Market: BCDA exceeded the US Market which returned -10.8% over the past year.

Price Volatility

Is BCDA's price volatile compared to industry and market?
BCDA volatility
BCDA Average Weekly Movement7.6%
Biotechs Industry Average Movement11.9%
Market Average Movement6.6%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.8%

Stable Share Price: BCDA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: BCDA's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a32Peter Altmanhttps://www.biocardia.com

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure.

BioCardia, Inc. Fundamentals Summary

How do BioCardia's earnings and revenue compare to its market cap?
BCDA fundamental statistics
Market CapUS$46.10m
Earnings (TTM)-US$12.34m
Revenue (TTM)US$1.33m

34.8x

P/S Ratio

-3.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BCDA income statement (TTM)
RevenueUS$1.33m
Cost of RevenueUS$8.75m
Gross Profit-US$7.42m
Other ExpensesUS$4.92m
Earnings-US$12.34m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.62
Gross Margin-560.30%
Net Profit Margin-931.32%
Debt/Equity Ratio0%

How did BCDA perform over the long term?

See historical performance and comparison